IDB-774

Developed for: Rift valley fever
Investigated by: IDBiologics, Inc. · Joint Program Executive Office Chemical, Biological, Radiological, and Nuclear Defense Enabling Biotechnologies

today NCT06925919 · Ph 1

2026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT06925919	Apr 2025 → Oct 2026 expected	Rift valley fever	IDBiologics, Inc.	Active not recruiting	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	IDB-774	“IDB-011 is comprised of IDB-774 and IDB-898, which will be administered as separate, consecutive intramuscular injections.” NCT06925919 ↗